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Abstract
Group B Streptococcus (GBS) is the leading cause of neonatal pneumonia, septicemia, and meningitis. We have previously
shown that in adult mice GBS glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an extracellular
virulence factor that induces production of the immunosuppressive cytokine interleukin-10 (IL-10) by the host early upon
bacterial infection. Here, we investigate whether immunity to neonatal GBS infection could be achieved through maternal
vaccination against bacterial GAPDH. Female BALB/c mice were immunized with rGAPDH and the progeny was infected
with a lethal inoculum of GBS strains. Neonatal mice born from mothers immunized with rGAPDH were protected against
infection with GBS strains, including the ST-17 highly virulent clone. A similar protective effect was observed in newborns
passively immunized with anti-rGAPDH IgG antibodies, or F(ab’)2 fragments, indicating that protection achieved with
rGAPDH vaccination is independent of opsonophagocytic killing of bacteria. Protection against lethal GBS infection through
rGAPDH maternal vaccination was due to neutralization of IL-10 production soon after infection. Consequently, IL-10
deficient (IL-10
2/2) mice pups were as resistant to GBS infection as pups born from vaccinated mothers. We observed that
protection was correlated with increased neutrophil trafficking to infected organs. Thus, anti-rGAPDH or anti-IL-10R
treatment of mice pups before GBS infection resulted in increased neutrophil numbers and lower bacterial load in infected
organs, as compared to newborn mice treated with the respective control antibodies. We showed that mothers immunized
with rGAPDH produce neutralizing antibodies that are sufficient to decrease IL-10 production and induce neutrophil
recruitment into infected tissues in newborn mice. These results uncover a novel mechanism for GBS virulence in a neonatal
host that could be neutralized by vaccination or immunotherapy. As GBS GAPDH is a structurally conserved enzyme that is
metabolically essential for bacterial growth in media containing glucose as the sole carbon source (i.e., the blood), this
protein constitutes a powerful candidate for the development of a human vaccine against this pathogen.
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Introduction
Streptococcus agalactiae, also named Group B Streptococcus (GBS),
is a Gram-positive encapsulated commensal bacterium of the
human intestine that colonizes the vagina of up to 30% of healthy
women. This bacterium is the leading cause of neonatal
pneumonia, septicemia, and meningitis [1,2,3,4]. Neonatal GBS
infections are acquired through maternal transmission and may
result in early-onset disease (EOD), which occurs within the first
week of life, or in late-onset disease (LOD), that occurs after the
first week and accounts for most meningitis cases and deaths
[3,5,6]. Despite early antimicrobial treatment and improvement in
neonatal intensive care, up to 10% of neonatal invasive GBS
infections are lethal and 25 to 35% of surviving infants with
meningitis experience permanent neurological sequelae [3].
Because recommendations for intrapartum antibiotic prophylaxis
(IAP) for mothers in labor at risk for GBS infection have been
widely implemented in many countries, the incidence of EOD has
declined to ,1/1,000 births, but the incidence of LOD has slowly
increased in the last decade [7]. An unexpected burden of case
fatalities among children aged less than 90 days caused by GBS
infection was recently reported in different European countries
[8,9,10]. Moreover, recent reports described the emergence of
antibiotic-resistant GBS strains likely caused by the widespread use
of IAP [11,12].
Maternal vaccination is the best alternative to IAP to deal with
GBS neonatal infections. Vaccines to prevent GBS disease have
been initially developed by coupling capsular polysaccharide (CPS)
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cines against nine GBS serotypes have been shown to be
immunogenic in animals, but the existence of distinct epitope-
specific capsular serotypes has hampered the development of a
global GBS vaccine [5,13]. Moreover, glycoconjugated vaccines
directed against the ten known serotypes of GBS would not protect
against infections by nontypeable GBS isolates that are increas-
ingly being reported [14,15,16,17].
The sequencing of numerous GBS genomes has accelerated
advances in vaccine development and new protein antigens have
been revealed using reverse vaccinology [5,18,19]. To avoid the
selection of mutants that escape immune recognition, the ideal
human GBS vaccine should be directed against structurally
conserved antigens that are essential for GBS virulence and/or
growth, but none of the hitherto described candidate antigens
fulfills these requisites.
The causes for the neonatal susceptibility to GBS infections are
still poorly understood. Newborn immune system is not completely
developed at birth, and undergoes an age-dependent maturation
until fully developed. Thus, invasive infections in the first days of
life pose serious threats for the newborn due to accentuated
deficiencies in both innate and adaptive arms of the immune
responses. Cases of early-onset GBS sepsis are usually character-
ized by an unexpectedly low number of neutrophils in infected
tissues [20,21,22,23]. This is commonly explained by the reduced
neutrophil chemotaxis and impaired granulocyte maturation
observed in neonates [24,25,26]. Of interest, high concentration
of plasma and cord blood IL-10 in preterm neonates evaluated for
sepsis was associated with mortality and is considered as an early
indicator of prognosis [27,28].
We have previously shown that the essential housekeeping
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
also acts as a GBS extracellular virulence factor that induces
rapid production of interleukin-10 (IL-10) by the host [29]. Adult
C57BL/6 mice (resistant to GBS infection) infected with a GBS
mutant strain that over-express GAPDH (oeGAPDH) had
increased bacterial colonization compared to mice infected with
wild-type (WT) GBS. Increased bacterial burden in oeGAPDH
infected C57BL/6 mice was accompanied by elevated serum
levels of IL-10. Consequently, acquired susceptibility of C57BL/6
mice to oeGAPDH infection was completely reverted in IL-10-
deficient animals [29]. This suggested that an exacerbated
production of IL-10 during GBS infection might facilitate
pathogen immune evasion. We demonstrate here that maternal
immunization with rGAPDH confers protection against GBS
infection in neonatal mice by abrogating the early IL-10
production detected upon the bacterial challenge. We also
demonstrate that blocking GAPDH-induced early IL-10 produc-
tion restores the recruitment of neutrophils in infected organs,
which is essential for pathogen elimination and host protection
against GBS infection.
Since GBS GAPDH is a structurally conserved enzyme that is
metabolically essential for bacterial growth in blood, it constitutes
an attractive target for the development of a human vaccine.
Results
GAPDH, a structurally conserved GBS protein
GAPDH, a key enzyme of the glycolytic pathway, is structurally
conserved in all 8 published GBS genomes (identity.99.8%).
Anti-rGAPDH IgG antibodies purified from sera of rGAPDH
immunized mice or rabbits were thus used to demonstrate the
presence of GAPDH in culture supernatants of ten unrelated GBS
clinical isolates (Figure 1A) belonging to different serotypes and/or
MLSTypes (Table S1). GBS GAPDH displays 44.7, 45.8 and
44.0% amino acid identity with rabbit, mice, and human
GAPDH, respectively (Figure 1B). However, western blot and
ELISA analysis revealed that rabbits and mice antibodies directed
against GBS rGAPDH do not react with human, mouse, or rabbit
GAPDH (Figure 2A and 2B). To favor the production of
antibodies recognizing linear buried epitopes, mice were immu-
nized with heat-denaturated rGAPDH (DT_rGAPDH). Anti-
DT_rGAPDH antibodies purified from the sera of these animals
did not show any cross-reactivity against mouse (self cross-
reactivity) or human GAPDH when analyzed by western blot
and ELISA (Figure 2C and 2E). These results are consistent with
the fact that the longest identical stretches observed between
eukaryotic and prokaryotic GADPH sequences are only 10-
aminoacid long (Figure 1B).
Maternal vaccination with rGAPDH protects neonates
from GBS infection
To test whether maternal immunization with rGAPDH
conferred protection to the offspring against GBS infection,
female BALB/c mice were immunized with rGAPDH in alum
adjuvant. Control mice were sham-immunized with the adjuvant
alone.
Pups born from sham-immunized or rGAPDH-immunized
females were infected intraperitoneally (i.p.) 48 h after birth with
5610
6 colony-forming units (CFU) of serotype III virulent GBS
strain NEM316. All but one mouse born from rGAPDH-
immunized mothers survived the infection (95% survival) whereas
22 out of 27 infected pups succumbed to GBS challenge in the
control group (18.5% survival) (Figure 3A). Most of the cases of
GBS meningitis and LOD are caused by a serotype III hyper
virulent clone, defined by multilocus sequence typing as ST-17
[30,31,32]. To better assess the effectiveness of maternal
vaccination with rGAPDH, pups born from sham- or rGAPDH-
immunized progenitors were i.p. infected 48 h after birth with
10
6 CFU of BM110, a serotype III GBS hyper virulent strain ST-
17 (Table S1). All ST-17 GBS challenged neonates born from
Author Summary
Streptococcus agalactiae (Group B streptococcus, GBS) is
the leading infectious cause of morbidity and mortality
among neonates. However, there is still no satisfactory
explanation of why neonates are so susceptible to GBS
infections. Intrapartum antibiotic prophylaxis (IAP) was
implemented in many countries but led to the emergence
of antibiotic-resistant GBS strains. Therefore, maternal
vaccination represents an attractive alternative to IAP.
Here, we show that the high susceptibility of newborn
mice to GBS infections is associated with their propensity
to produce elevated amounts of immunosuppressive
cytokine IL-10. We also demonstrate that IL-10 impairs
neutrophil recruitment into infected organs thus prevent-
ing bacterial clearance. We identified extracellular GAPDH
as the GBS factor that induces the high IL-10 production
detected early upon neonatal infection. We show that
maternal vaccination with recombinant GAPDH confers
robust protective immunity against lethal infection with a
GBS hyper-virulent strain in mice offspring. This protection
can also be obtained either by antibody neutralization of
GBS GAPDH or by blocking IL-10 binding to its receptor. As
GBS GAPDH is an essential protein for bacterial growth, it
is present in all GBS strains and thus constitutes an
appropriate target antigen for a global effective vaccine
against this pathogen.
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21.4% in neonates born from rGAPDH-immunized mothers
(Figure 3B). The protective effect conferred by rGAPDH maternal
immunization was also observed in neonate mice infected by the
subcutaneous (s.c.) route with 2.5610
4 BM110 CFU. As shown in
Figure 3C, none of the mice born from sham-immunized mothers
survived this infectious challenge whereas only 23% of mice born
from rGAPDH-immunized mothers died. Altogether, these results
show that maternal vaccination with rGAPDH protected the
offspring against GBS infections, including those caused by the
hyper virulent strain BM110.
Passive immunization with anti-rGAPDH F(ab’)2-
fragments protects newborns against GBS ST-17
challenge
Pups born from rGAPDH-immunized mothers presented
increased serum titers of anti-rGAPDH IgG antibodies when
compared with those born from sham-immunized mothers (Figure
S1). To evaluate the importance of these maternal antibodies in
the newborn protection against GBS infection, neonatal mice were
passively immunized with purified anti-rGAPDH IgG antibodies
12 h prior to GBS challenge. The passive antibody transfer
conferred protection against infection caused by the virulent
NEM316 or hyper virulent BM110 strains (Figure 4A and 4B).
Anti-rGAPDH IgG antibodies conferred a similar protection to
neonate mice infected by the s.c. route (data not shown). As
described by others [33], we observed that GAPDH is present at
the cell surface of GBS strains (Figure S2) and, it was therefore
conceivable that protection conferred by anti-rGAPDH antibodies
could be due to an enhanced opsonophagocytosis-mediated killing
of GBS. However, anti-rGAPDH IgG antibodies did not
enhanced in vitro phagocytosis or complement-mediated killing of
GBS BM110 cells (Figure 4C). This indicated that protection
conferred by anti-rGAPDH antibodies was not mediated by these
mechanisms. Furthermore, complete protection against GBS
infection was observed in neonate mice treated with purified
anti-rGAPDH F(ab’)2 fragments 12 h before i.p. infection with
BM110 strain. In contrast, all pups that received the same amount
of control F(ab’)2 fragments died within the first 3 days upon the
infectious challenge (Figure 4D). Altogether, these results demon-
strate that enhanced opsonophagocytic killing or complement
activation did not mediate the observed protective effect of anti-
rGAPDH antibodies.
GBS GAPDH induces early IL-10 production in newborn
mice
We have previously described a rise in IL-10 serum levels in
adult mice treated with rGAPDH [29]. As shown in Figure S3, a
Figure 1. GAPDH is a conserved GBS protein. (A) Extracellular proteins from culture supernatants of different GBS clinical isolates were
separated by SDS-page and analyzed by western-blot using anti-rGAPDH IgG obtained from rGAPDH-immunized rabbits. rGAPDH was used as a
positive control. The data are representative of four independent experiments. (B) Multiple alignment of the aminoacid sequences of the human,
rabbit, mice, and GBS GAPDH. The green vertical bars below the consensus sequences indicate identical aminoacid at the same position in all four
sequences. The two heavy black lines delineate the two conserved 10-aminoacid stretches of identity.
doi:10.1371/journal.ppat.1002363.g001
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mice 1 h after i.p. injection of rGAPDH. Inactivation of rGAPDH
enzymatic activity did not reduce this effect (Figure S3). This result
indicates that IL-10 production induced by GBS GAPDH is
independent of the dehydrogenase activity. We have also
described that adult mice infected with GBS oeGAPDH mutant
strain presented higher serum IL-10 levels than counterparts
infected with WT GBS [29]. Thus, we also quantified the levels of
serum IL-10 in mice pups at early times after GBS infection. As
shown in Figure 5, infection of newborn mice with GBS WT strain
NEM316 resulted in a rapid increase of serum IL-10 concentra-
tion. Maternal rGAPDH vaccination or treatment with anti-
rGAPDH F(ab’)2 fragments completely abrogated the elevated
amount of IL-10 found in the sera of infected pups born from
sham-immunized mothers or treated with control F(ab’)2
(Figure 5A and 5B). Altogether, these results strongly suggest that
the elevated IL-10 serum levels detected upon infection were due
to GBS GAPDH.
Protection conferred by anti-rGAPDH antibodies is
associated with inhibition of early IL-10 production in
GBS-infected pups
The results presented above indicate that newborn susceptibility
to GBS infection is most probably associated with early IL-10
production induced by GAPDH. To confirm this hypothesis, IL-
10 deficient (IL-10
2/2) pups and WT controls were infected with
this bacterium. In agreement with our hypothesis, IL-10
2/2 pups
were more resistant (78%) to GBS infection compared to WT
controls (10%) (Figure 6A). To demonstrate further the essential
role of IL-10 in neonatal susceptibility to GBS, newborn mice were
treated with anti-IL-10 receptor (IL-10R) mAb 12 h before
Figure 2. Antibodies against GBS GAPDH do not cross-react with human, rabbit or mouse GAPDH. (A and B) Reactivity of rabbit and
mouse anti-rGAPDH IgG against GBS, human (Hu), mouse (M) or rabbit (R) GAPDH were assessed by (A) western-blot or (B) ELISA analysis. (C and D)
Reactivity of anti-rGAPDH IgG purified from the sera of mice immunized with heat-denaturated rGAPDH (DT_rGAPDH) against GBS, human or mouse
GAPDH, were assessed by (C) western-blot or (D) ELISA analysis. ND, not detected.
doi:10.1371/journal.ppat.1002363.g002
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treated with anti-IL-10R mAb survived (86% or 82%, respectively)
while all control pups died (Figure 6B and 6C). No additional
protection was observed when newborn mice were treated
simultaneously with anti-IL10R mAb and anti-rGAPDH IgG
(Figure 7). Altogether, these results indicate that protection
achieved using anti-GAPDH antibodies is due to inhibition of
host IL-10 production. Several studies have shown that GBS can
survive for prolonged periods within the phagolysosome of
macrophages [34,35,36,37]. Interestingly, we observed that the
simultaneous addition of anti-rGAPDH IgG’s, or anti-IL10R
mAb, and GBS cells to bone marrow-derived macrophages
(BMMw) cultures inhibits the bacterial survival (Table 1). This
result, combined with those shown in Figure S3, indicates that the
Figure 3. Maternal immunization with rGAPDH protects newborn mice from GBS-induced death. Pups born from sham- or rGAPDH-
immunized mothers were infected i.p. 48 h after birth with (A) 5610
6 NEM316 CFU or with (B) 10
6 CFU of the ST-17 hyper virulent strain BM110. (C)
Mice pups were infected s.c. 48 h after birth with 2.5610
4 CFU of BM110. The results represent data pooled from three independent experiments. In
all figures depicting survival experiments, the numbers between parentheses represent the number of animals that survived the different infectious
challenges versus the total number of infected animals. Statistical differences (P values) between immunized versus sham-immunized groups are
indicated.
doi:10.1371/journal.ppat.1002363.g003
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IL-10 production induced by GBS GAPDH.
GAPDH blocks neutrophil recruitment in injured organs
upon GBS infection
A plausible explanation for the observed protection induced by
maternal vaccination with rGAPDH could be that GAPDH-
mediated early IL-10 production, elicited upon the GBS challenge
in newborns, inhibits the initiation of a host-protective inflamma-
tory response. Neutrophil recruitment is an early event associated
with protection against bacterial infection in neonates. Moreover,
lack of neutrophil recruitment into infected organs has already
been associated with neonatal susceptibility against GBS infections
[21,22,23,38]. To confirm that neutrophil recruitment into
infected organs is an essential event for newborn protection
against GBS infection, neutrophils of newborn mice were depleted
by treatment with anti-Ly6G (1A8 clone) monoclonal antibodies
(Figure S4). We observed that either blocking IL-10 signaling with
neutralizing antibodies or anti-rGAPDH antibody treatment was
not sufficient to protect neutropenic pups infected with a lethal
inoculum of GBS (Figure 8).
In addition, we assessed the numbers and frequency of
neutrophils in the liver and lungs of GBS NEM316-infected pups
previously treated with anti-rGAPDH IgG or anti-IL10R mAb.
The frequency and the total number of neutrophils quantified
18 h after GBS challenge in the analyzed organs of infected pups
Figure 4. Passive immunization with purified anti-rGAPDH antibodies protects newborn mice from GBS-induced death. anti-rGAPDH
IgG or control IgG (80 mg) were injected i.p. into mice pups and 12 h after the immunization they were infected i.p. with (A) 5610
6 NEM316 CFU or
with (B) 10
6 CFU of the ST-17 hyper virulent strain BM110. The results represent data pooled from two independent experiments. (C) Upper panel:
BMM were stimulated in vitro with 10
6 CFU of GBS NEM316 (or BM110) plus 25 mg/mL of anti-rGAPDH IgG’s, or 10% of serum containing anti-GBS
antibodies, and incubated for 30 min at 37uCi n5 %C O 2. Data represent the mean + SEM. Results are representative of 3 independent experiments.
Statistical differences (P values) are indicated. Lower panel: complement-mediated killing of GBS. Mice peripheral blood leukocytes were stimulated
with 10
6 CFU of GBS NEM316 (or BM110) plus 25 mg/mL of anti-rGAPDH IgG’s, or 10% of anti-GBS serum, and 5% of rabbit serum was added to the
mixture as a source of complement. After 2 h of incubation period at 37uC, GBS CFU were evaluated on agar plates. Data represent the mean + SEM.
Results are representative of 2 independent experiments. Statistical differences (P values) are indicated. Similar results were obtained when a higher
concentration (100 mg/mL) of anti-rGAPDH IgG’s was used. (D) Pups were passively immunized with 80 mg of anti-rGAPDH F(ab’)2 fragments, or
control (Fab’)2 and infected 12 h later with 10
6 CFU of the ST-17 hyper virulent strain BM110. The results represent data pooled from two
independent experiments.
doi:10.1371/journal.ppat.1002363.g004
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non-infected pups (data not shown). Treatment with either anti-
rGAPDH IgG or anti-IL-10R mAb prior to GBS infection
significantly increased the neutrophil recruitment in organs
(Figure 9A and 9B). Consistently, the organs of pups treated with
anti-IL10R mAb or anti-rGAPDH IgG contained significantly less
bacteria than those of untreated pups (Figure 9C). These results
indicate that an efficient neutrophil recruitment into infected
organs is crucial for neonatal protection against GBS infection
whereas impaired neutrophil recruitment facilitates GBS coloni-
zation. Moreover, no bacterial colonization was detected three
weeks after GBS infection in the brain or in any other organ of
pups born from rGAPDH-immunized mothers and infected with
NEM316 or with the ST-17 hyper-virulent strain BM110 (data not
shown). These results indicate that rGAPDH-maternal vaccination
is also effective in preventing LOD.
Figure 5. GAPDH neutralization abolishes IL-10 production observed in newborn mice early upon GBS infection. Serum IL-10
concentration in mice pups was measured 1 h and 4 h after i.p. infection with 5610
6 NEM316 CFU (A) born from sham- or rGAPDH-immunized dams
or (B) passively immunized with anti-rGAPDH F(ab’)2 fragments or control F(ab’)2. Data represent the mean + SEM. Results are a representative
example out of 3 independent experiments. A minimum of 8 animals per group was used in each experiment. Statistical differences (P values)
between immunized versus sham-immunized groups (A) or between pups treated with anti-rGAPDH F(ab’)2 fragments versus controls (B) are
indicated.
doi:10.1371/journal.ppat.1002363.g005
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Newborns are highly susceptible to infectious disease and
deficiencies of key components of the complement cascade
combined with the inability to produce high amounts of antibodies
against T-independent antigens greatly impairs their ability to
respond to encapsulated bacteria [39]. Absence of previous
interactions with environmental microbes also implies that no
immunological memory exists against specific antigens, which
means that the acquired immune protection of newborns relies
mainly on antibodies passively transferred from their mothers [40].
In addition, previous reports indicate that neonatal innate immune
cells are less efficient in producing Th1-type inflammatory
cytokines, but more competent in producing the immunosuppres-
sive cytokine IL-10 upon Toll-like receptor (TLR) engagement by
microbial products [41,42,43,44]. Moreover, newborn mice
leukocytes are highly committed to produce increased amounts
of IL-10 [44,45], as also shown in human neonates [41,43,46]. As
report in this work, high levels of serum IL-10 could be detected in
the sera of GBS infected newborn mice early (1 h and 4 h) upon
infection. This result is in agreement with a previous report by
Cusumano et al. [47], showing that elevated levels of plasma IL-10
were detected in newborn mice 24 h and 48 h upon GBS
challenge. These authors suggested a host protective role for IL-10
in the outcome of neonatal GBS sepsis as pre-treatment of
newborn mice with recombinant IL-10 improved their survival
upon a lethal s.c. GBS challenge [47]. Nevertheless, they also
showed that a therapeutic administration of this cytokine (24 h
after the bacterial challenge) did not improve survival. This would
limit its use in human therapies because neonatal GBS infection is
usually acquired before or during labor [3,5,6].
Our results revealed that blocking IL-10 signaling through anti-
IL-10R mAb administration was sufficient to confer protection
against a bacterial challenge using either the s.c. or i.p. routes.
Thus, they contrastingly indicate that IL-10 has a deleterious effect
in the newborn host resistance to GBS infection. The increased
resistance of IL-10-deficient neonates to GBS infection reported
here constitutes further support for a deleterious effect of IL-10 in
host resistance to GBS. As shown here, the GBS GAPDH induced
host IL-10 production detected early after bacterial infection.
IL-10 is produced by multiple cell types and inhibits leukocyte
activation, pro-inflammatory cytokine production and down-
regulates the expression of anti-microbial molecules on activated
phagocytes [48,49,50,51]. IL-10 also inhibits production of CC
and CXC chemokines by activated monocytes [52,53,54]. Since
these chemokines are implicated in the recruitment of leukocytes
during inflammation, IL-10 production indirectly inhibits leuko-
cyte trafficking to inflamed tissues [50,55,56].
IL-10 production was already associated with host susceptibility
against different pathogens [24,45,57,58,59,60,61]. We show here
that treatment of pups with either anti-IL10R mAb or anti-
rGAPDH IgG prior to the GBS challenge increased the neutrophil
recruitment in liver and lungs that is triggered upon infection.
Neutrophil recruitment is a crucial event in the host effector
immune response to GBS [21,62,63] and, consequently, lack of
neutrophil infiltration in infected sites has been reported in cases of
severe early-onset GBS sepsis [21,22,23,38]. Thus, neutralization
of GAPDH, and hence blockade of the induced IL-10 production,
allowed an effective immune response at an early stage of infection
that prevented death of pups. Moreover, pups protected by
maternal immunization with rGAPDH presented no GBS CFU in
the brain, lungs, and liver 3 weeks upon the infectious challenge.
This indicates that protection achieved by this vaccination strategy
might prevent LOD.
The recruitment of neutrophils into infected tissues is very
important to restrain bacterial replication. Thus, qualitative and
quantitative deficiencies in the neutrophils of newborns may
explain the observed susceptibility to GBS infections. Indeed,
newborn neutrophils have reduced adhesion capabilities due to
reduced expression of adhesion molecules [24,25] and they
produced a limited number of microbicidal molecules. Moreover,
the number of these cells is also reduced when compared to adults
Figure 7. Simultaneous injection of anti-rGAPDH IgG’s and anti-IL10R mAb does not increase survival of newborn mice infected
with GBS BM110. Newborn mice were treated i.p. with 100 mg of anti-IL10R mAb, anti-rGAPDH IgG’s, or simultaneous with anti-IL10R mAb and
anti-rGAPDH IgG’s (anti-rGAPDH + anti-IL10R) 12 h before s.c. injection of 2.5610
4 CFU of GBS BM110. Control pups received 100 mg of control IgG’s.
P,0.0001 between anti-IL10R-, anti-rGAPDH- and anti-rGAPDH+antiIL-10R-treated pups and controls.
doi:10.1371/journal.ppat.1002363.g007
Figure 6. Impairment of IL-10 signaling confers protection to newborn mice against GBS infection. (A) IL10
2/2 and WT pups were
infected i.p. with 5610
6 NEM316 CFU (results represent data pooled from two independent experiments). (B) Newborn mice were injected i.p. with
anti-IL10R mAb (anti-IL10R) or isotype control IgG (100 mg) and 12 h later were challenged i.p. with 5610
6 NEM316 CFU (results represent data
pooled from three independent experiments). (C) Newborn mice were injected i.p. with anti-IL10R mAb (anti-IL10R) or isotype control IgG (100 mg)
and 12 h later were challenged s.c. with 2.5610
4 BM110 CFU (results represent data pooled from four independent experiments). Statistical
differences (P values) between IL-10
2/2 and WT pups (A) or between immunized versus sham-immunized groups (B and C) are indicated.
doi:10.1371/journal.ppat.1002363.g006
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[26]. As a consequence, the intra-cellular and extracellular killing
of pathogens is greatly impaired in neonates [64]. However, our
results indicate that, despite these serious functional defects, the
neutrophils of neonates can control the GBS infections as long as
the inhibitory effect of IL-10 is blocked. Importantly, IL-10
blockade with a specific mAb did not significantly decreased the
elevated serum TNF-a levels detected upon GBS infection in
neonate mice [47]. This further suggests that impairment of
neutrophil recruitment rather than inhibition of pro-inflammatory
cytokines could be the prominent effect of IL-10 produced in the
course of neonatal GBS infection.
Neonatal sepsis is a pathological condition associated with
elevated levels of pro-inflammatory cytokines, including IL-1b,
TNF-a, and IL-6. However, it has been previously described that
cord blood or plasma IL-10 concentration is significantly increased
in neonatal sepsis, constituting an early indicator of prognosis
[27,28]. Of interest, it was also reported that high IL-10 levels are
found in children at initial phases of fulminant septic shock
[65,66]. This indicates that early IL-10 production, instead of
being a physiological attempt to counterbalance the elevated levels
of pro-inflammatory cytokines, could be a predisposing factor for
disease. Our results are in accordance with this hypothesis and
they provide the first evidence that the lack of neutrophil
recruitment in infected organs combined with elevated cord blood
IL-10 concentration may account for neonatal susceptibility to
GBS infection. Hence, the discovery of GAPDH as an
extracellular virulence factor of GBS that induces an early IL-10
production by the infected host could be a significant contribution
to our understanding of the pathology of neonatal infections.
GAPDH is a promising candidate for a human GBS vaccine
because it is an essential metabolic enzyme that also plays a critical
role in virulence. Our results show that maternal vaccination with
rGAPDH protects the offspring against GBS lethal infection,
including those caused by the hyper virulent ST-17 clone, which is
responsible for most cases of neonatal meningitis [31,32,38]. As a
consequence, maternal rGAPDH vaccination might efficiently
protect against both EOD and LOD [5,67,68]. We demonstrated
that passive immunization of neonates with GAPDH-specific IgG
antibodies is sufficient to confer protection against GBS infection.
Importantly, rGAPDH maternal vaccination prevents the early
production of IL-10 in GBS infected pups and similar protective
effect was obtained when GAPDH-specific antibody F(ab’)2
fragments were used instead of whole IgG. These results indicate
that neutralization of GAPDH-mediated IL-10 production, rather
than complement activation or bacterial opsonophagocytosis,
accounts for the observed protection. The extracellular GAPDH
was detected at the bacterial surface and in culture supernatants of
GBS isolates, which suggests that neutralization of its biological
activity by antibody binding should not be sterically impaired by
surface capsular polysaccharides. Recently, Margarit et al. showed
that pili proteins could be used as a human vaccine to prevent
GBS infections but, due to sequence variability, a combination of 3
antigens was required to confer protection against 94% of
contemporary GBS strains [19]. It is likely that under selective
pressure this vaccine will select GBS variants expressing new pili
antigens, as shown for Neisseria gonorrhoeae [69,70,71,72,73]. In
contrast, since it is an essential and highly conserved metabolic
enzyme, GAPDH is unlikely to accumulate rapidly escape
mutations or rearrangements under such a selective immune
pressure.
Taken together, our results demonstrate that extracellular
GAPDH confers a selective advantage to GBS for survival in the
infected host. In particular, GBS GAPDH acts on the host
immune system to elicit IL-10 production thereby favoring
bacterial colonization and survival. As we demonstrated that
GBS GAPDH was still able to induce host IL-10 production upon
exposure to an oxidative agent, this mechanism may still operate
within the highly oxidative environment resulting from the host
inflammatory response. Our data highlight the critical role played
by this immunosuppressive cytokine in determining susceptibility
to GBS infection at an early time after birth. Our results also show
that GBS-associated pathology can be counteracted either by
rGAPDH vaccination or IL-10 neutralization. In the future, it will
be essential to explore the use of either strategy to induce
protection towards other human neonatal pathogens.
Materials and Methods
Bacterial strains
Relevant characteristics of the GBS strains used in this study are
summarized in Table S1. Escherichia coli BL21 (DE3) strain
Table 1. Inhibition of GBS intracellular survival in cultured
BMM .
Intracellular bacterial count
a
(log10CFU ± SEM)
NEM316 BM110
2h 2 4h 2h 2 4h
RPMI 5.2160.18 6.4960.88 5.4060.17 6.6760.58
anti-rGAPDH 4.8260.08 0.0060.00** 5.1960.13 0.0060.00**
anti-IL10R 4.9760.13 0,6661.15** 5.1460.12 0.0060.00**
aBMM were infected in vitro for 2 h with GBS NEM 316 or BM110 at MOI of
10 CFU per macrophage. After three washes in HBSS containing penicillin and
streptomycin, infected macrophages were further incubated in RPMI medium
containing 10% FCS and antibiotics. At indicated time points, the cells were
washed with antibiotic-free HBSS, lysed with saponin, and the CFU estimated
by plating serial dilutions of the lysate onto agar plates. ** P,0.0001 compared
with RPMI control at the same time point.
doi:10.1371/journal.ppat.1002363.t001
Figure 8. Neutrophils are essential for neonatal protection
against GBS infection. Neutropenic mice pups were injected i.p. with
100 mg of anti-rGAPDH antibodies (n=11), anti-IL-10R mAb (n=14) or
control antibodies (n=16) 12 h before i.p. infection with 5610
6 CFU of
NEM316. Results represent data pooled from three independent
experiments.
doi:10.1371/journal.ppat.1002363.g008
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production of recombinant GAPDH (rGAPDH) as described
previously [29]. GBS was grown in Todd-Hewitt broth or agar
(Difco Laboratories) containing 0.001 mg/mL of colistin sulphate
and 0.5 mg/mL of oxalinic acid (Streptococcus Selective Supple-
ment, Oxoid) and E. coli was cultured on Luria-Bertani medium.
Bacteria were grown at 37uC.
Animals
Male and female BALB/c mice (6-8 weeks old) were purchased
from Charles River. IL-10-deficient BALB/c (IL-10
2/2) mice
were kindly provided by Dr. A. O’Garra (National Institute for
Medical Research, London, U.K.). New Zealand White rabbits
were purchased from Charles River. Animals were kept at the
animal facilities of the Institute Abel Salazar during the time of the
experiments.
Ethics statement
This study was carried out in strict accordance with the
recommendations of the European Convention for the Protection
of Vertebrate Animals used for Experimental and Other Scientific
Purposes (ETS 123) and 86/609/EEC Directive and Portuguese
rules (DL 129/92). The animal experimental protocol was
approved by the competent national authority Direcc ¸a ˜o Geral
de Veterina ´ria (DGV) (Protocol Permit Number: 0420/000/000/
2008). All animal experiments were planned in order to minimize
mice suffering.
Preparation of active and inactive recombinant GAPDH
Recombinant GAPDH (rGAPDH) was purified as described in
detail previously [29]. Enzymatically inactive rGAPDH (inact-
rGAPDH) was obtained by pretreatment of the enzyme with
500 mMH 2O2. The lack of enzymatic activity upon inactivation
was confirmed using a previously described enzymatic assay for
GAPDH [29].
Maternal immunizations with rGAPDH
Recombinant GAPDH was used for maternal immunization
assays. Female mice were injected intraperitoneally (i.p.) twice,
with a 3-week intervening period, with 200 mL of a preparation
containing 25 mg of rGAPDH in a 1:20 PBS/alum suspension
(Aluminium hydroxide Gel; a kind gift of Dr Erik Lindblad,
Figure 9. GAPDH-induced IL-10 blocks neutrophil recruitment in injured organs. (A) Flow cytometric analysis of Ly6G expression on total
lung or liver leukocyte cells from newborn mice treated i.p. with 100 mg of purified anti-rGAPDH IgG antibodies (anti-rGAPDH), of anti-IL10R mAb
(anti-IL10R), or control antibodies (IgG and isotype control) and infected with 5610
6 NEM316 CFU 12 h after antibody treatment. Pups were sacrificed
18 h after the bacterial challenge. The percentage of Ly6G
+ cells is indicated. Results are representative of three independent experiments. (B) Total
number of Ly6G
+ cells (neutrophils) per organ observed in the different used groups. Data are the mean + SEM. Results are representative of 4
independent experiments and a minimal of 5 animals per group was used. Statistical differences (P values) between groups are indicated. (C) GBS
CFU in the liver, lungs and brain of infected pups treated with control IgG (n=11), isotype control IgG (n=11), anti-IL10R (n=8), or anti-rGAPDH
(n=8). Statistical differences (P values) between groups are indicated.
doi:10.1371/journal.ppat.1002363.g009
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control animals received 200 mL of a 1:20 PBS/alum suspension.
Immediately after the second injection, female and male mice
were paired. Females were monitored closely during gestation and
the day of delivery was recorded. Serum anti-rGAPDH antibody
titers were determined by ELISA as previously described [29].
Antibody treatments
Antibody treatments were performed in newborn BALB/c mice
12 h prior to GBS infection. For passive immunizations, pups were
injected i.p. with 100 mg of anti-rGAPDH IgG antibodies or anti-
rGAPDH F(ab’)2 fragments. Control animals received the same
amount of control IgG’s or F(ab’)2 fragments issued from control
IgG’s. For IL-10 signaling blocking, 100 mg of anti-IL10R
antibodies (1B1.3a, Schering-Plough Corporation) were adminis-
tered i.p. and control animals received the same amount of
matched isotype control antibody.
Challenging infections of newborn mice
Newborn mice were infected i.p. with 5610
6 cells of GBS
NEM316 or 10
6 cells of GBS BM110 (ST-17), 48 h after birth in a
maximum volume of 40 mL. Subcutaneous (s.c.) infections were
performed 48 h with 2.5610
4 cells of GBS BM110 after birth in a
total volume of 20 mL. Survival curves were determined in a 12-
day experiment period and newborns were kept with their mothers
during the entire time of the experiment. The liver, lungs, and
brain of infected pups were aseptically removed at indicated time
points and homogenized in PBS and serial dilutions of
homogenized organs were plated on Todd-Hewitt agar to
enumerate bacterial CFU.
Purification of anti-rGAPDH IgG antibodies
Adult mice or rabbit were immunized twice with 25 mgo f
rGAPDH in a PBS/alum suspension as described above and sera
were collected 10 days after the second immunization. Pooled
serum samples were applied to a Protein G HP affinity column
(HiTrap, GE Healthcare Bio-Sciences AB) and purified IgG
antibodies were then passed through an affinity column with
immobilized rGAPDH (Hi-trap NHS-activated HP, GE Health-
care Bio-Sciences AB). Control IgGs were obtained from sera of
mice or rabbits sham-immunized with a PBS/alum suspension
and purified on a Protein G HP affinity column. Purified IgG
antibody fractions were further equilibrated in PBS and stored at -
80uC in frozen aliquots.
Preparation of anti-GBS serum
GBS-specific antiserum was obtained from mice immunized i.p.
twice (with a 3-week interval) with isopropanol-fixed 10
5 GBS cells
plus alum (total volume). Serum from immunized animals (Anti-
GBS serum) was obtained from retro-orbital bleeding 10 days after
the second immunization.
Preparation of F(ab’)2 fragments
F(ab’)2 fragments from anti-rGAPDH or control IgGs were
obtained using IgG1 F(ab) and F(ab’)2 Preparation Kit (Pierce)
used according to manufacturer’s instructions.
Opsonophagocytic assays
Bone marrow-derived macrophages (BMM ) purified as
described previously [74] were plated in 96-well plates
(10
5 BMM / well) and stimulated for 30 min at 37uC 5%CO2
with 10
6 CFU of GBS BM110 (or NEM316) in the medium alone
(RPMI), the medium containing 25 mg/mL of anti-rGAPDH
IgG’s, or medium with 10% of serum containing anti-GBS IgG
antibodies. After this incubation period, the plates were washed
three times with HBSS to remove extracellular bacteria. To
enumerate intracellular GBS CFU, 10% saponin (1:100 dilution)
was added to wells and serial dilutions of supernatant were plated
onto agar plates.
Complement-mediated killing assay
Blood from adult mice was collected in heparinated tubes and
diluted 1:1 in HBSS. 10
6 GBS NEM316 (or BM110) CFU with
25 mg/mL of anti-rGAPDH IgG’s or 10% of serum containing
anti-GBS IgG antibodies were then added. Rabbit serum (5%) was
added to the mixture as a source of complement. After 2 h of
incubation at 37uC, serial dilutions of the mixture were plated onto
agar plates to evaluate complement-mediated GBS killing.
Intracellular survival of GBS in macrophages
The BMMı ˆ, obtained as described previously [74], were
infected with GBS strains NEM316 and BM110 at a macro-
phage:bacteria ratio of 1:10 in RPMI containing 10% FCS.
Microplates were incubated for 2 h at 37uCi n5 %C O 2 for GBS
phagocytosis. After this period, culture supernatants of infected
macrophages were removed by aspiration and cells were washed
three times (10 min for each wash) with HBSS containing
penicillin (100 IU/mL) and streptomycin (50 mg/mL) to kill
extracellular bacteria. Infected macrophages were further incu-
bated in RPMI medium containing 10% FCS and the same
concentrations of antibiotics. To quantify intracellular GBS, the
supernatants containing antibiotics were removed, the cells were
washed with antibiotic-free HBSS, lysed with saponin (0,1% final
concentration), and the CFU were estimated by plating serial
dilutions of the lysate onto agar plates.
Neutrophil recruitment
Neutrophil recruitment in liver and lungs of infected pups was
evaluated by flow cytometry analysis. Briefly, 18 h after GBS
infection, the organs were collected, gently homogenized in HBSS
(Sigma), and passed through glass wool to remove cellular
aggregates. PerCP/Cy5.5 anti-mouse Ly-6G antibody (clone
1A8; Biolegend) was used for neutrophil detection. Cells were
analyzed by an Epics XL cytometer (Beckman Coulter).
Neutrophil depletion
Newborn mice were depleted of neutrophils by treatment with
anti-Ly6G antibodies (clone 1A8, Biolegend). Antibody treatment
was performed twice, 12 h before and immediately after GBS
challenge. Each pup was injected with a total of 80 mg of anti-Ly-
6G antibodies.
Interleukin-10 quantification
IL-10 was quantitated in the serum of newborn mice with an
ELISA kit (eBioscience) used according to the manufacturer’s
instruction.
Detection of GAPDH
The presence of GAPDH in the culture supernatants of GBS
strains was visualized by Western-blot analysis. Extracellular
proteins were isolated as described previously [29]. The reactivity
of purified anti-rGAPDH IgG antibodies obtained from the serum
of rGAPDH immunized mice or rabbits against self or human
GAPDH, was determined by Western-blot analysis or ELISA.
Human, rabbit, and mouse GAPDH were purified from human
rGAPDH Vaccination Against Neonatal GBS Disease
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described [75,76].
Statistical analysis
Student’s T test was used to analyze the differences between
groups. Survival studies were analyzed with the log-rank test. A P
value,0.05 was considered statistically significant.
Supporting Information
Figure S1 Increased anti-rGAPDH IgG serum titers in
mice pups born from rGAPDH-vaccinated mothers.
Newborn mice from rGAPDH-immunized mothers present higher
serum anti-rGAPDH IgG antibody titers than controls born from
sham-immunized mothers. Anti-rGAPDH antibody titers were
determined by ELISA. Results are pooled data from three
independent experiments (n=13 or 17 for pups born from
sham-immunized or rGAPDH-immunized mothers, respectively).
(TIF)
Figure S2 GAPDH is present at GBS cell surface.
Fluorescence microscopy analysis of GBS cells using anti-
rGAPDH polyclonal antibodies purified from rGAPDH-immu-
nized rabbits and revealed with FITC-conjugated anti-rabbit IgG
(Green). Bacterial DNA was stained with DAPI (blue). GBS cells
incubated with (A) secondary antibody only, (B) with anti-
rGAPDH plus secondary antibody, or (C) with anti-rGAPDH
plus rGAPDH to inhibit antibody binding to surface-localized
antigen.
(TIF)
Figure S3 Active or enzymatically inactive rGAPDH
induces IL-10 production. IL-10 concentration in the sera of
newborn mice 1 h after i.p. injection with 50 mg of rGAPDH or
rGAPDH pre-treated with 500 mMH 2O2 (inact_rGAPDH).
Control mice were injected with PBS. Results are pooled data
from two independent experiments (n=9 for controls, 8 for
rGAPDH and 7 for pups treated with inact_rGAPDH). Statistical
differences (P values) between groups are indicated.
(TIF)
Figure S4 Treatment of newborn mice with anti-Ly6G
antibodies induces neutropenia. Pups were treated i.p. 36 h
and 48 h after birth with 40 mg of anti-Ly6G (clone 1A8) mAb or
with the same amount of an isotype matched control antibody.
The frequency of blood neutrophils was determined 4 h after the
last injection by FACS analysis using anti-Gr-1 mAb (clone RB6-
8C5).
(TIF)
Table S1 Phenotypic and genotypic characteristics of
the GBS human isolates used in this study.
(DOC)
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